# Adagene Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Adagene Inc.).

## Overview

Adagene Inc. is a biotechnology company focused on discovering and developing antibody-based cancer therapies. It operates through a network of subsidiaries across the United States, China, Hong Kong, Australia, Singapore, and Switzerland, and its shares trade on Nasdaq through ADSs.

## Products & services

• SAFEbody® masked antibody platform
• Antibody-drug conjugate (ADC) candidates
• Monoclonal antibody cancer therapeutics
• Clinical-stage oncology immunotherapies
• Discovery and development collaboration programs

- **Platform technology licensing** (50%) — Licensing of the SAFEbody technology platform for use in masked antibody and ADC programs.
- **Clinical oncology candidates** (35%) — Company-owned therapeutic programs in clinical and preclinical development for cancer indications.
- **Research and discovery services** (15%) — Collaborative discovery, engineering, and preclinical development work for partners.

- SAFEbody® masked antibody platform
- Antibody-drug conjugate (ADC) candidates
- Monoclonal antibody cancer therapeutics
- Clinical-stage oncology immunotherapies
- Discovery and development collaboration programs

## Customers

Adagene’s customers and partners are mainly biopharmaceutical companies that license its antibody engineering technology or co-develop oncology candidates. Its therapeutic programs are ultimately designed for cancer patients, but commercial value is created through collaborations with drug developers that fund and advance development. The company also works with scientific and clinical research ecosystems supporting antibody discovery and translational oncology.

- **Pharmaceutical collaboration partners** (primary) — License SAFEbody and co-develop masked antibody and ADC programs.
- **Oncology drug developers** (primary) — Partner on preclinical and clinical programs to access Adagene's platform.
- **Clinical research networks** (secondary) — Run trials and provide data for the company’s cancer candidates.
- **Patients with solid tumors** (secondary) — End users of the therapies being developed for cancer treatment.

- Large biopharma partners licensing SAFEbody technology
- Oncology developers co-funding preclinical and clinical programs
- Clinical investigators running trial sites and studies
- Research institutions supporting antibody discovery work
- Future patients with cancer indications targeted by the pipeline

## Geography

Adagene is headquartered in the Cayman Islands structure, with operational and scientific presence centered in Suzhou, China and San Diego, United States. Its subsidiary footprint also spans Hong Kong, Australia, Singapore, and Switzerland, reflecting a cross-border research and partnering model. The business is globally oriented because licensing and clinical development collaborations can involve partners and trial activity across multiple regions.

- **Asia** (45%) — Operational footprint concentrated in China and other Asian subsidiaries.
- **North America** (35%) — U.S. corporate and operating presence plus Nasdaq listing exposure.
- **Europe** (10%) — Swiss subsidiary supports international research and partnering.
- **Oceania** (10%) — Australian subsidiary supports development operations.

- Corporate domicile in the Cayman Islands
- Research and development base in Suzhou, China
- U.S. operating presence in San Diego and Delaware entities
- Subsidiaries in Hong Kong, Singapore, Australia, and Switzerland
- Global partnering model with cross-border clinical and licensing exposure

## Strategy

Adagene’s strategy is centered on advancing SAFEbody as a differentiated masking platform for antibody and ADC programs. It uses partnerships to extend the technology into multiple programs while continuing to move its own oncology candidates through clinical development. The model depends on translating platform validation into milestone payments, development progress, and eventual royalties or product value.

- **Validate SAFEbody through partnerships** (short-term) — Partner programs can prove the platform and create milestone/royalty economics.
- **Advance clinical oncology pipeline** (medium-term) — Clinical data are needed to support future partnering, value creation, and potential commercialization.
- **Expand application of masking technology** (medium-term) — Broader use cases increase the addressable partner pipeline and platform relevance.

- Advance SAFEbody as the core differentiated technology
- Convert collaboration milestones into non-dilutive funding
- Broaden partnered ADC and masked antibody programs
- Progress internal oncology assets through clinical studies
- Use AI and computational biology to improve antibody design

## Risks

Adagene is exposed to clinical development risk, because its value depends on whether its oncology candidates show acceptable efficacy and safety in trials. It also faces partner concentration and execution risk, since milestones and royalties depend on collaborators advancing programs, and biotech funding/valuation can be highly sensitive to data readouts. As a global developer with operations in the U.S. and China, it also faces cross-border regulatory, foreign exchange, and localization risks.

- **Clinical failure of oncology candidates** [critical] — Pipeline value depends on trial results, and early-stage oncology programs can fail at efficacy or safety readouts.
- **Partner dependency** [high] — Milestone and royalty revenue rely on collaborators continuing development and selecting programs.
- **Foreign exchange volatility** [medium] — Operating cash flows and reported results are affected by multiple currencies across subsidiaries.
- **Regulatory and cross-border execution** [high] — Drug development requires approvals and trial execution across jurisdictions with different requirements.

- Clinical trials may fail to show efficacy or acceptable safety
- Partner milestones depend on collaborator development decisions
- Future royalties depend on downstream commercialization success
- Cross-border operations create regulatory and FX volatility
- Biotech financing conditions can affect development continuity

## Accounting

Revenue is driven by licensing and collaboration arrangements, so the timing of milestone recognition and any related performance obligations is a key accounting judgment. The company also records fair value changes on warrant liabilities and foreign currency translation effects, both of which can materially move reported earnings even when operating performance is unchanged. As a clinical-stage biotech, research and development spending is another major area to watch because it rises as programs move through trials and preclinical work.

- **Licensing and collaboration revenue** — Affects the timing and volatility of reported revenue.
- **Fair value of warrant liabilities** — Can materially change net loss period to period.
- **Foreign currency translation** — Affects equity and comprehensive loss, especially with RMB and USD movements.
- **Research and development capitalization policy** — Directly drives operating expense trends as programs advance.

- Collaboration revenue depends on milestone timing and performance obligations
- Warrant liabilities are remeasured at fair value through earnings
- Foreign exchange translation can move equity and comprehensive loss
- R&D expense reflects clinical and preclinical program progression
- Share-based and development-related judgments affect reported loss

---

*Last updated: 2026-09-28T11:57:35.938956+00:00*